Hims & Hers Health Surges to Ninth in Trading Volume with $54.14 Billion Day

On April 29, 2025, Hims & Hers Health (HIMS) saw a significant surge in trading volume, reaching $54.14 billion, marking a 468.56% increase from the previous day. This surge placed Hims & Hers at the ninth position in terms of trading volume for the day. The stock price of Hims & Hers Health rose by 23.03%, marking the second consecutive day of gains, with a total increase of 24.74% over the past two days.

Hims & Hers Health announced a strategic partnership with Novo Nordisk, a Danish pharmaceutical company. This collaboration will allow Hims & Hers users to access Novo Nordisk's weight-loss drug, Wegovy, starting this week. The telehealth company had previously benefited from selling compounded versions of popular weight-loss drugs during a supply shortage. However, the Food and Drug Administration (FDA) announced in February that Novo Nordisk's Ozempic and Wegovy are no longer in shortage, and compounders have until mid-May to stop selling compounded versions of these medications.

Hims & Hers will offer a bundled package that includes all dose strengths of Wegovy and a Hims & Hers membership, starting at $599 or more. This move comes after Hims & Hers announced earlier this month that it would add Eli Lilly's weight-loss drugs, including Mounjaro and Zepbound, to its platform. Eli Lilly clarified that it has no affiliation with Hims & Hers and that Zepbound can be prescribed by any licensed healthcare professional.

With this partnership, Hims & Hers is poised to continue its growth trajectory, having nearly tripled in value over the past 12 months. The telehealth provider is scheduled to report its first-quarter results next Monday, which will provide further insights into the company's performance and future prospects.